MBGL vs RYTM Comparison

Mobility Global, which spun out of S&P Global on July 1, 2026, is a market-leading provider of automotive data, analytics, and software. Mobility Global consists of two segments: Carfax and B2B. Carfax is the firm's largest segment by both revenues and profits and is the market leader in the vehicle history reports, or VHR, space. The B2B segment provides auto manufacturers (original equipment manufacturers, or OEMs), auto suppliers, dealers, and others with a range of marketing, sales, strategy, and planning solutions. In 2025, Mobility Global generated 83% of its revenue in the US.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.